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Health Care System (SUS) perspective. We also studied the value of dasatinib versus 
nilotinib. METHODS: A cost-utility lifetime Markov model was developed to calcu-
late the incremental cost per Quality-Adjusted Life Year (QALY). Disease progression 
depended on the best treatment response rates taken from dasatinib clinical trials. 
Transition probabilities and utilities were estimated from published literature. Drugs 
costs were obtained according to ofﬁcial prices and standard government discounting 
procedures. Since nilotinib does not have a published price in Brazil, the lowest inter-
national price found on the internet was used. Resource utilization was based on 
clinical survey. Both costs and effects were discounted annually at 5.0%. The robust-
ness of the results was assessed through deterministic and probabilistic sensitivity 
analysis. RESULTS: In the base case, lifetime treatment resulted in dominance of 
dasatinib in CP versus both imatinib 400 mg and nilotinib, and an incremental cost-
effectiveness ratio (ICER) of about a52,000/QALY for AP and approximately 
a51,000/QALY for BP against imatinib. Sensitivity analysis showed pharmaceutical 
costs as the most important driver of the result. CONCLUSIONS: Compared to 
 imatinib 400 mg and nilotinib, dasatinib is associated with increased QALYs in all 
phases and lower overall costs in CP. So dasatinib is the dominant strategy for the 
treatment of chronic phase CML patients who are resistant to imatinib. Since clinical 
outcomes for imatinib 800 mg for advanced phases are unsatisfactory, dasatinib 
140 mg is a reasonable option for imatinib-resistant CML patients in accelerated and 
blast phases.
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OBJECTIVES: The costs of second line treatment for non small cell lung cancer 
(NSCLC) has dramatically increased during the last decade. The objective of this phase 
III, randomized, multicenter study was to compare from the payer’s perspective the 
economical impact of two widely used treatments: pemetrexed versus docetaxel. 
METHODS: This study included progressive NSCLC: docetaxel 75 mg/m2 (arm A) 
versus pemetrexed 500 mg/m2 (arm B) every three weeks. The number of subjects 
was determined to ﬁnd a second line direct cost difference of 10% between the two 
arms (A  0.05, B  0.20). The analysis recorded: transportation, drug, administration 
(outpatient or inpatient) and adverse events costs. Average and 95% conﬁdence 
intervals, cost-differences were calculated by non parametric methods (bootstrap, SAS 
software). RESULTS: 150 patients were enrolled between February 2006 and June 
2008. There were no differences between the two arms in terms of sex, age, performans 
status, weight loss, body surface, history. TTP was 2.8 m [2.26–4.23] for arm A, 
2.53 m [2.16–4.00] for arm B (p  0.85). The mean number of cycles was 3.7 (o 1.9) 
for arm A and 3.6 (o 1.75) for arm B. There were no differences for overall toxicities 
(p  0.55), and for grade 1–2 toxicities. In the opposite, there was a signiﬁcantly dif-
ference in term of overall grade 3–4 toxicities: 39/75 for arm A (52%) versus 25/75 
(33%) for arm B (p  0.02). In terms of chemotherapy costs, arm B was more costly: 
a777,082.76 versus a513,700.42 (51%). In terms of global costs, the difference was 
decreased at 37%. CONCLUSIONS: Chemotherapy with pemetrexed was more 
expansive for 2d line NSCLC treatment. The difference decreased according to adverse 
events and administration costs. Cost-effectiveness and sensitivity analyses will be 
presented at the meeting.
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OBJECTIVES: We analyzed the impact of informal caregiving on caregiver’s work-
place productivity. Workplace productivity of caregivers attending to patients (pts) 
with advanced renal cell cancer (advRCC) treated with temsirolimus (TEMSR) was 
compared with that of caregivers attending to pts treated with interferon-alfa (INFa). 
In addition, we evaluated the reaction of informal caregiving in both treatment groups. 
METHODS: Data were analyzed from phase 3 trial of pts with untreated, poor-
 prognosis advRCC. Pts were randomly assigned to 25 mg TEMSR weekly, or INFa 
(titrated to 18 mU) 3 times weekly. Caregiver work productivity and activity impair-
ment questionnaire (WPAI-CG), as well as a caregiver reaction assessment instrument 
(RAI), was administered at baseline and at 4-wk intervals until wk-32. Participation 
for caregiver study was on a voluntary basis. For the current analysis, we evaluated 
WPAI and RAI at pts’ last visits. ANCOVA model was used with baseline WPAI-CG, 
RAI, and measures of disease severity as covariates. RESULTS: Of 416 pts entered in 
the TEMSR (n  209) and IFNa (n  207) arms, data were available for 174 caregivers. 
About 50% of participating caregivers were employed (55% in TEMSR arm & 45% 
in INFa arm [p  0.1724]). Caring for advRCC pts was associated with substantial 
carer burden; on average, caregivers reported absenteeism of 11 hrs/wk and a 27% 
reduction in productivity at work. Caregivers caring for TEMSR pts reported signiﬁ-
cantly lower absenteeism (22% vs. 40%, p  0.0339), lower overall work productivity 
loss (34% vs. 49%, p  0.0178), and lower overall impairment in regular activity 
(29% vs. 38%, p  0.0305) than caregivers caring for INFa pts. Based on RAI ques-
tionnaire, caregivers of TEMSR pts reported a signiﬁcantly lower burden on their daily 
schedule compared with caregivers of INFa pts (14.0 vs. 15.9, p  0.0043). CONCLU-
SIONS: Although the study had 42% (174/416) caregiver participation rate, TEMSR 
therapy in advRCC is associated with reductions in caregiver burden.
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OBJECTIVES: The aim was to assess the cost of dynamic contrast -enhanced ultra-
sound (DCE -US) with quantiﬁcation of tumor perfusion parameters from raw linear 
data on a large sample of patients and tumors. METHODS: Eighteen French hospitals 
participated in the study. All consecutive exams performed to assess targeted treatment 
efﬁcacy were registered. The cost of each DCE -US was computed based on resource 
use data collected during the study: the duration of each exam, the type of staff and 
equipment and the amount of US contrast agent. To value resources we used unit 
costs at the Gustave-Roussy Institute. A sensitivity analysis was conducted. RESULTS: 
A total of 1452 DCE -US were recorded in 367 patients with mainly hepatocellular 
carcinoma (22%), or metastasis from kidney cancer (33%), colon cancer (12%) or 
melanoma (10%). Sorafenib, sunitinib and bevacizumab were the three most frequent 
treatments. The median number of DCE -US per patient was 5. Quantiﬁcation of 
perfusion parameters was possible in 881 DCE -US (62%). The mean duration of a 
DCE -US was 28 minutes. The radiologist’s intervention lasted 24 minutes on average. 
Quantiﬁcation of the tumor perfusion parameters lasted 17 minutes. The mean cost 
of a DCE -US was estimated at a173. In the sensitivity analysis, the cost ranged from 
a152a to a197. The cost of the baseline DCE -US was 10% higher than subsequent 
exams. A second bolus injection was required in 1/5 baseline exams to choose a rele-
vant target at treatment initiation. CONCLUSIONS: The cost of DCE -US is higher 
than conventional US mostly because of contrast agent use which accounts for half 
the cost of the procedure. Despite a 20% rate of re -injections and longer exams at 
baseline, the cost variability of DCE-US is rather low. This new technique strongly 
challenges CT perfusion in the monitoring of targeted treatments: it is cheaper and 
reduces the risk of radiation-related cancers.
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OBJECTIVES: Organizational Analysis and Economic Evaluation of the Diagnostic 
process for breast cancer in Italian hospitals. METHODS: Multicenter, retrospective 
study involving 21 hospitals. Target population: patients whose diagnostic test results 
(ecography and/or mammography) and clinical examinations raised suspicion of 
malignancy and required further tests. Diagnostic procedures analysed: Cytological 
examination, Core Biopsy (CB), Vacuum-Assisted Breast Biopsy (VABB), on eco-
graphic and stereotactic guide, and Surgical biopsy. Based on the collected informa-
tion, a diagnosis path was built. Each path’s segment included a single procedure or 
a sequence of tests. Data on proportion of patients submitted to each path were col-
lected from centers enrolled. Resource use data including: time effort, consumables 
and technological supply. Unit costs were based on hospitals data and ofﬁcial tariffs 
(National Tariff Nomenclature for specialist services). Direct costs of the diagnostic 
process were determined from the hospital perspective. Cost of “Diagnostic Uncer-
tainty” was estimated considering further examinations needed. RESULTS: Data of 
29,457 patients were collected (about 15,000 patients/year). For the 45.8% of 
patients, radiologists choose the ecoguided cytological examination as ﬁrst exam; 
23.4% of patients with an ecovisible lesion performed a CB ecoguided; the 26.4% 
with no ecovisible lesion was subjected to a stereotactic VABB. Impact of further 
exams on the cost of diagnostic process increased the procedural costs by 356% for 
the ecoguided CB (a83 vs. a378) and the 36% of the stereoguided VABB cases (a683 
vs. a1.868). CONCLUSIONS: The most used procedures were CB and ecoguided 
cytological exam for ecovisible lesions and stereoguided VABB for non ecovisible 
lesions. Diagnostic path cost increased with respect to procedure cost, mostly relevant 
for CB, due to the use of surgical biopsy. The real economic impact is due, not only 
in direct costs of the exam itself, but also to those connected to the probability that 
others have to follow.
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OBJECTIVES: Chemotherapeutic drugs for mNSCLC patients are tested in “optimal 
conditions” in randomised control trials at prescribed dosing schedules. In clinical 
practice however, providers determine dosing schedules according to physician 
